Combined Statement of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities
Net loss		$ (157,125)	$ (804)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		2
Stock-based compensation		66
Amortization of debt discount		243
Acquired in-process research and development		78,897
Change in fair value of warrant liabilities (includes related party amounts of $59,031 and $0, respectively)	$ 57,776	59,060
Change in fair value of convertible promissory notes (includes related party amounts of $1,053 and $22, respectively)		4,928	22
Changes in operating assets and liabilities:
Prepaid expenses and other current assets (includes related party amounts of $17, and $8, respectively)		(3,147)	(36)
Accounts payable and accrued expenses (includes related party amounts of $186, and $32, respectively)		1,603	89
Accrued interest (includes related party amounts of $483 and $13, respectively)		2,347	8
Net cash used in operating activities		(13,126)	(721)
Cash flows from investing activities
Cash paid for purchased in-process research and development		(25,118)
Cash paid for property, plant and equipment		(26)
Net cash used in investing activities		(25,144)
Cash flows from financing activities
Proceeds from issuance of common stock			2
Proceeds from issuance of convertible promissory notes		88,324	850
Net proceeds from issuance of long-term debt		24,850
Issuance costs associated with Initial Public Offering (IPO)		(1,299)
Net cash provided by financing activities		111,875	852
Net increase in cash		73,605	131
Cash and cash equivalents – beginning of period		879
Cash and cash equivalents – end of period	$ 74,484	74,484	$ 131
Supplemental disclosure of cash flow information
Interest paid		549
Supplemental disclosure of noncash investing and financing activities
Exchange of accrued interest for convertible promissory notes		27
Issuance of common stock warrants in connection with long-term debt		419
Unpaid initial public offering costs		714
Final interest payment fee		2,063
Takeda License
Supplemental disclosure of noncash investing and financing activities
Issuance of Takeda Warrants in connection with Takeda License		47,894
Issuance of common stock in connection with Takeda License		$ 5,885